EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation

Carles Tolosa-Ridao,Enric Cascos,Luis Gerardo Rodríguez-Lobato,Alexandra Pedraza,María Suárez-Lledó,Paola Charry,María Teresa Solano,Julia Martinez-Sanchez,Joan Cid,Miquel Lozano,Laura Rosiñol,Jordi Esteve,Álvaro Urbano-Ispizua,Francesc Fernández-Avilés,Carmen Martínez,Enric Carreras,Maribel Díaz-Ricart,Montserrat Rovira,María Queralt Salas
DOI: https://doi.org/10.1038/s41409-024-02270-x
2024-03-23
Bone Marrow Transplantation
Abstract:This study investigates the interaction between endothelial activation, indirectly measured using EASIX, and the probability of presenting cardiac adverse events (CAE) during the first year after allo-HCT. The 437 consecutive adults undergoing PB allo-HCT from 2012 and 2021 were included. EASIX was retrospectively calculated before and during the first 6 months after allo-HCT and transformed to log2-base to conduct the statistical analysis. The median age was 53, 46 (10.5%) patients had previous history of cardiac disease, MAC allo-HCTs were performed in 186 (42.6%) patients, and PTCY was administered in 242 (55.5%). The 1-year incidence of CAE was 12.6% ( n = 55). The most prevalent cardiac events were heart failure and arrhythmias, 32.7% and 23.6% respectively, and the day +100 mortality rate of these patients was 40.5%. During the first 6 months after allo-HCT, EASIX trends were significantly higher in patients who developed CAE. Regression analyses confirmed that higher log2-EASIX values were predictors for higher risk for CAE during the first year after allo-HCT. This analysis identifies a significant association between higher endothelial activation, indirectly measured using EASIX, and higher risk for cardiac toxicity diagnosed during the first year after allo-HCT and extends the applicability of EASIX for identifying patients at risk for CAE.
oncology,immunology,hematology,transplantation
What problem does this paper attempt to address?